[Asia Economy Reporter Seo So-jeong] GC Green Cross (CEO Heo Eun-cheol) announced on the 26th that it confirmed an increase in thrombin (one of the proteins involved in blood coagulation) levels proportional to the concentration of the drug in the plasma of hemophilia patients treated with the hemophilia antibody therapeutic ‘MG1113’.
The research team, jointly participated by GC Green Cross and Mokam Life Science Research Institute, confirmed the blood coagulation effect and mechanism of MG1113 on the plasma of hemophilia patients with abnormalities in blood coagulation factors and on animals induced with hemophilia.
The team obtained data showing normalization of blood coagulation time and blood firmness, and through animal testing, demonstrated improvement in bleeding and levels of blood coagulation factors. The results of this study were published in the international academic journal Research and Practice in Thrombosis and Haemostasis.
The company explained that this study is meaningful in preparing a new treatment alternative for hemophilia patients.
MG1113 is made as an antibody that promotes blood coagulation, differing from existing hemophilia treatments that directly inject the deficient coagulation factors into the blood. It can be used by patients who have developed resistance to existing drugs and can be used regardless of the type of hemophilia.
Additionally, it has a longer half-life and a high-concentration formulation compared to existing treatments, allowing for subcutaneous injection. By enabling injection under the skin instead of painful intravenous administration, patient convenience can be improved.
Heecheon Kwak, a researcher at GC Green Cross and author of this paper, said, "Since hemophilia patients need to receive medication regularly throughout their lives, reducing the burden of administration on patients is key in therapeutic research," adding, "We hope that MG1113, developed purely with domestic technology, will help improve the quality of life for patients."
MG1113 is currently undergoing domestic Phase 1 clinical trials to verify safety and plans to proceed with follow-up studies soon.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
